News | December 14, 2023
Pfizer expects 2024 revenue between US$ 58.5 to US$ 61.5 billion
Anticipates approx. US$8 billion in revenues for Comirnaty and Paxlovid
Anticipates approx. US$8 billion in revenues for Comirnaty and Paxlovid
The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome
Venus Remedies is supplying the drug to many countries like Colombia, Thailand, Tanzania, Morocco, Myanmar, Indonesia, Saudi Arabia, Malaysia, Zimbabwe, Sri Lanka, Pakistan, Kenya, and Botswana
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
Covaris is a global leader in the development and deployment of end-to-end solutions for high-throughput genomic and proteomic analysis
The product has been in-licensed from Strides and will be commercialized by Amneal
The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone
The divestment is a part of Fortis' ongoing portfolio rationalization strategy
The newly established business will be looking for high-quality, mid- to late-stage assets, clinically focused on the United States market
Lupin Vilfuro-G is the only FDC that uniquely combines Vilanterol, Fluticasone Furoate and Glycopyrronium Bromide
Subscribe To Our Newsletter & Stay Updated
